|Share Price at beginning of the year was 20.5p, and tonight it has fallen to 15.5p, so a 24.39% drop in 3 months. Let's hope we are not going to test the next fib level 'down' !!|
|I'm puzzled by why the price has dropped back again. Given the forecasts, this will be a very profitable company in time, but perhaps investors are running out of their time in waiting. Yes, it is a long haul, but one that will come through in a positive manner in the next year to two, in my belief. In the meantime, I can just pick up a few more from time to time when weakness, such as now, hits. Averaging down is speculative/tricky/risky, yes; but worth it with TRX, IMHO.|
|Hmmm, looks like I added a few more shares too soon, but hey-ho, I'm sure Mr Woodford has a few more shares than me that has been affected !!!!!!!!!!!!!!!!!!|
|I shall be around bamboo! I moved into HUR rather strong, so if you see that succeed, then you'll know I'm here again in force.|
|Ray, luminoso, Thanks for letting us know.
This is a turning into a rather long haul, so don't blame you at all.
I am committed to holding.
The only opportunity that you could miss perhaps would be a bid, but that seems unlikely in the near term. The meniscus and tendon products have been delayed and I guess there will be time to get back in when the new trial is completed, if you still like the look of it. There will be a CE mark, then product launch, etc etc etc....|
|I'm in pretty much the same position. Out but watching.|
|I'm out completely now. But I'm only trying to catch something sooner elsewhere which hopefully I'll make a return that will let me get back in here before good news strikes!
|with Results coming up sometime soon, then it was just toooooooo tempting not to buy another 8334 shares at 17.90p this afternoon|
|01 March 2017
Tissue Regenix Group plc
Innovative Technology Contract Awarded
DermaPure(R) Receives Innovative Technology Contract from Vizient, Inc.
Leeds, 01 March 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces effective from today its wound care product, DermaPure(R), has been awarded an Innovative Technology contract from Vizient, Inc., the largest member-owned health care company in the United States.
The contract was based on a recommendation of DermaPure(R) by hospital representatives who serve on a Vizient member-led council with expertise in this category. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization's care delivery and business model.
Antony Odell, CEO, Tissue Regenix Group plc commented: "The approval by Vizient under their Innovative Technology contracting process reinforces Vizient member support for DermaPure(R). We look forward to working with Vizient members to bring DermaPure(R) to the wider patient population."
"Due to the number of products and services being released and marketed as 'innovative', member hospitals find value in the thorough innovative technology review process in place at Vizient to help them identify products worth consideration for use at their own facilities," said Debbie Archer, director of procurement and leader of Vizient's Innovative Technology program for suppliers. "After a full review of DermaPure, Vizient's member council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology contract."|
|Just been looking back through some of the company announcements over the last few months which re-assures me of my holding and maybe that on this dip, or subsequent dips, then it might be prudent to start adding again.
From the announcement on 28th November :
“The launch of OrthoPure™ XT remains on track for H1 2017, with CE mark approval in the same period. The first distribution agreements within Europe have been signed, indicators of the strong commercial and clinical support for OrthoPure™ XT, in preparation for rapid commercialisation in key European markets once approval is granted.
Peter Hamer, Commercial Director TRX Orthopaedics Ltd: "We are extremely encouraged by the initial results returned from the study. Having entered our first distributor agreements, which highlight the demand and market opportunity for OrthoPure™ XT, we remain on track for launch of OrthoPure™ XT by the end of H1 2017.”
So anytime in the next 4 months if all goes to plan, and that should see a significant rise in the share price if we are lucky ??|
|Antony Odell, CEO, will be presenting to investors at the Biotech Capital Conference on 21st February. For more details and to register, click here: https://tinyurl.com/gtd5lt6|
|02 February 2017
Tissue Regenix Group plc
DermaPure(R) added to the Federal Supply Schedule
Leeds, 02 February 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces DermaPure(R) a decellularized dermal allograft, utilising Tissue Regenix's patented dCELL(R) Technology, has been included on the United States Department of Veteran Affairs (VA) Federal Supply Schedule (FSS) via their distribution agreement with ERA Health LLC dba Veteran's Health Medical Supply (VHMS).
The FSS services the largest integrated healthcare system in the US, covering almost 9 million lives, many being military veterans, and includes 152 hospitals and 800 community based outpatient clinics(1) . Wound care is particularly important within this patient sector, with it being estimated that 1 in 4 military veterans suffers from diabetes, much higher than the US average where 9% of the total population are diabetes sufferers.
The inclusion on the FSS further strengthens the commercial position of DermaPure(R) within both the inpatient and outpatient settings and offers this customer segment an efficient and effective clinical and economic solution. As announced on the 06 December 2016, DermaPure(R) was awarded a GPO new technology award after a thorough four step review process determined that the technology offers unique attributes in comparison to the other available treatment options.|
|Hi zinzanno8, I thought that the Financial Year was moved to end of December as you have said, but I couldn't find the notification when I was flipping through the RNS's. Must admit I didn't have a lot of time earlier and as having to be a full time carer 24/7 is very tiring, especially when I get towards the end of the day.|
|I believe the financial year has been adjusted from January to December in line with Medtech peers so end of FY16 (as its billed again) was 31st December 2016. Should bring results forward at least by a month...The piece to watch is how are they going to fund the £20 million requirement for ongoing working capital? By a joint venture or a cash call?|
|So the share price inevitably has dropped under the pressure of the recent sells. Buying opportunity ??. Already got my boots full up, so will have to pass on getting more.
However, it will be interesting to see the end of year Financial Results (end of Financial Year was yesterday 31-01-2017) but looking back on last years results then they didn't get announced until May 2016.
Looking back at recent RNS's then Mr Woodford was still accumulating in December just gone, and the Board has been strengthened - so still a lot of positivity here.
I can't see any reason for me to shed any more of my shares, so have to be patient and hope I have some spare cash to put into the new tax year ISA (only 9 weeks away guys) whereby I may add a few more then.|
|Yes, it does cp.|
|Ray, like yourself I have reduced my holding by 30% but that was only because I was too heavy here.
Going back to my post of 3 days ago, the shares holding up well with all the recent selling, then trying to put 2 + 2 together to make 4 -- TRX recently added a new director -- "Mr Devlin brings a wealth of experience having worked on both domestic and international mergers and acquisitions, business transformations, large and small scale business start ups, joint ventures and disposals throughout the last 20 years." -- might be that TRX may be looking to "offload a division" (as has been mentioned they could do before) sometime soon to concentrate on the ones left, like not having too many balls in the air to juggle at any one time !! Probably my 2 + 2 = 7 and way off the mark, but with so many shares sold recently, and the share price still staying strong, makes you think doesn't it ??|
|I've sold 50% of my holding, having decided it is better employed elsewhere for now. I'll hopefully be able to get back to my original stake before great things happen. Who knows?
So far, I have done the right thing!|
|With so many "sell" trades this month, the share price has been holding up very well. Does the market know good news that us pi's have not been made aware of yet ?. Maybe the U.S.A has been a better than expected source of revenue at this stage of things ? Maybe the company will be able to give us an update sometime soon.|
|06 January 2017
Tissue Regenix Group plc
Appointment of Group Finance Director
Leeds, 06 January 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announce the appointment of Paul Devlin as Group Finance Director and Company Secretary with immediate effect.
Mr Devlin brings a wealth of experience having worked on both domestic and international mergers and acquisitions, business transformations, large and small scale business start ups, joint ventures and disposals throughout the last 20 years. He joins Tissue Regenix from an interim assignment for a private equity house and prior to this, was Group Finance Director at Fletchers Bakeries Limited, which was sold to Finsbury Food Group plc in October 2014.
Antony Odell, CEO, Tissue Regenix Group commented: "We are delighted to welcome Paul as Group Finance Director. He will play a pivotal role in the strategic direction of Tissue Regenix over the coming years and the experience he brings will be invaluable to the company as we accelerate the breadth, depth and scope of our commercial activity."
Full name: Paul John Devlin
- Fletchers Bakeries Limited; Director, January 2008-June 2016
- Nicholas and Harris Limited; Director, December 2014-March 2016
- Oakdale Bakeries Limited, Oakdale Holdings Limited; July 2005-Feb 2007; companies placed in administration, no action or investigation by FCA or other bodies|
|There's a lot of resistance around the 21 to 21.5 mark, which causes selling as weak holders lack patience. In my view, that's a good time to buy or add (and as I said before, I'm so heavy here that adding would unbalance my portfolio, but I'm happy to hold). To make a poor pun: this is patient capital! Just look at the product(s), which are in demand and selling overseas too, so the £ weakness will help. Take a break from following the price every day - except maybe to buy on weakness - and wait for the real returns to kick in, which they will, IMHO.|
|Hell of a good bet tho'!|
|Hardly anything to chew on? And not one comment on this thread...so it obviously bowled everyone over?
But heyho, patience is a virtue, so they say? But when you get to my fairly great age! Patience is a luxury.|